Acute pancreatitis is an uncommon adverse effect of sodium-glucose linked transporter 2 inhibitors (SGLT2is). Their use has notably increased in recent years, hence clinical suspicion is key in patients recently started on these drugs. We report the case of an 83-year-old male patient who was admitted for a first acute pancreatitis episode of unclear etiology that eventually was attributed to dapaglifozin, a SGLT2i in widespread use.